Log In
Print
BCIQ
Print
Print this Print this
 

SAF-301

  Manage Alerts
Collapse Summary General Information
Company Lysogene S.A.S.
DescriptionIntracerebrally administered adeno-associated virus (AAV) serotype 10 (AAV10) vector encoding N-sulfoglucosamine sulfohydrolase (SGSH; HNS) and sulfatase modifying factor 1 (SUMF1)
Molecular Target N-sulfoglucosamine sulfohydrolase (SGSH) (HNS) ; Sulfatase modifying factor 1 (SUMF1)
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)
Latest Stage of DevelopmentPhase I/II
Standard IndicationMucopolysaccharidosis
Indication DetailsTreat mucopolysaccharidosis IIIA (MPS IIIA, Sanfilippo type A syndrome)
Regulatory Designation
Partner RegenxBio Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today